Patents Assigned to VAXIL BIOTHERAPEUTICS LTD
-
Patent number: 11179452Abstract: The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: GrantFiled: November 7, 2016Date of Patent: November 23, 2021Assignee: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Patent number: 11135277Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: July 11, 2019Date of Patent: October 5, 2021Assignees: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Patent number: 10350284Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: March 31, 2019Date of Patent: July 16, 2019Assignees: Lior Carmon, VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20190185558Abstract: The invention concerns methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti SP antibodies are capable of detecting cell surface expression of these SP domains and therefore they can be used in methods of diagnosis and/or therapy. In one aspect, the invention provides a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. The invention is specifically exemplified with antibodies directed against the signal peptide of MUC1 which is expressed on the surface of various cancer cells, and with signal peptide domains of Mycobacterium tuberculosis. In other aspects the invention provides methods for diagnosis of disease based on the detection of endogenously produced anti SP antibodies.Type: ApplicationFiled: August 14, 2017Publication date: June 20, 2019Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventors: Lior Carmon, Riva KOVJAZIN
-
Patent number: 10245309Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: May 8, 2017Date of Patent: April 2, 2019Assignees: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Patent number: 9732153Abstract: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.Type: GrantFiled: September 13, 2012Date of Patent: August 15, 2017Assignee: VAXIL BIOTHERAPEUTICS LTD.Inventors: Lior Carmon, Riva Kovjazin
-
Patent number: 9642903Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: July 15, 2010Date of Patent: May 9, 2017Assignees: LIOR CARMON, VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20170072036Abstract: The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: ApplicationFiled: November 7, 2016Publication date: March 16, 2017Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior CARMON
-
Patent number: 9487574Abstract: The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: GrantFiled: September 23, 2007Date of Patent: November 8, 2016Assignee: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20140220028Abstract: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.Type: ApplicationFiled: September 13, 2012Publication date: August 7, 2014Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventors: Lior Carmon, Riva Kovjazin
-
Publication number: 20120177677Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: July 15, 2010Publication date: July 12, 2012Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20100074925Abstract: The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: ApplicationFiled: September 23, 2007Publication date: March 25, 2010Applicant: VAXIL BIOTHERAPEUTICS LTDInventor: Lior Carmon